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ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma 
(HCC), especially in non-cirrhotic individuals. The rs641738 C>T MBOAT7/TMC4 variant predisposes 
to progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD 
patients, the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08-2.55; n=765), 
particularly in those without advanced fibrosis (p<0.001). The risk T allele was linked to 3’-UTR 
variation in MBOAT7 and to reduced MBOAT7 expression in patients without severe fibrosis. The 
number of PNPLA3, TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC 
independently of clinical factors (p<0.001), but did not significantly improve their predictive accuracy. 
When combining data from an independent UK NAFLD cohort, in the overall cohort of non-cirrhotic 
patients (n=913, 41 with HCC) the T allele remained associated with HCC (OR 2.10, 1.33-3.31). Finally, 
in a combined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease 
(n=1121), the T allele was independently associated with HCC risk (OR 1.93, 1.07-3.58). In conclusion, 
the MBOAT7 rs641738 T allele is associated with reduced MBOAT7 expression and may predispose to 
HCC in patients without cirrhosis, suggesting it should be evaluated in future prospective studies 
aimed at stratifying NAFLD-HCC risk. 
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INTRODUCTION 
Following the epidemics of obesity and insulin resistance and the recent improvements in the 
prevention and treatment of viral hepatitis, nonalcoholic fatty liver disease (NAFLD) is becoming a 
major cause of hepatocellular carcinoma (HCC) in Western countries 1, 2, 3, 4.  NAFLD affects 16-38% of 
the general population worldwide 5 and is leading cause of cirrhosis, the main risk factor for HCC. 
However, HCC frequently develops in NAFLD patients even in the absence of severe liver fibrosis 6. The 
high prevalence of NAFLD and development of HCC in non-cirrhotic patients unaware of being at risk 
renders therefore classic HCC screening strategies aimed at early diagnosis and curative treatment 7 
unfeasible. Thus, there is an urgent need of non-invasive biomarkers able to stratify NAFLD-HCC risk, 
especially in patients without severe fibrosis 8, 9.  
Inherited factors contribute to HCC susceptibility, and strong familial aggregation is observed 10. 
NAFLD too has a strong heritable component 11, and the PNPLA3 I148M variant is the main common 
genetic determinant of hepatic fat content and of progressive NAFLD 12, 13, 14, 15. The mechanism is 
related to accumulation of the mutated protein 16, which interferes with lipid droplets remodeling in 
hepatocytes 15, 17, 18, and with retinol release by hepatic stellate cells 19, 20. The PNPLA3 variant predicts 
HCC development in European patients with NAFLD 21, suggesting that genetic risk factors may prove 
helpful to select high-risk individuals for screening 21, 22, 23, but has a low specificity to be used as single 
prognostic biomarker 24. Furthermore, the PNPLA3 variant also predisposes to HCC in other liver 
diseases associated with steatosis, namely alcoholic liver disease (ALD) and chronic hepatitis C (CHC) 
23. The TM6SF2 E167K variant also predisposes to progressive NAFLD by altering the secretion of very 
low-density lipoproteins 25, 26, 27, but its direct role in HCC predisposition is disputed 26, 28.  
The MBOAT7/TMC4 locus rs641738 C>T sequence variant predisposes to liver fibrosis development in 
individuals with excessive alcohol intake 29 and chronic hepatitis C 30, and to the development and the 
progression of NAFLD in individuals of European descent 31, 32. However, whether the rs641738 
variant is also associated with HCC risk is still unknown. Aim of this study was therefore to evaluate 
whether the rs641738 variant predisposes to HCC in NAFLD patients stratified by the presence of 
severe fibrosis, and in other liver diseases characterized by hepatic steatosis. 
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RESULTS 
 
The Italian NAFLD cohort 
The clinical features of Italian NAFLD patients stratified by HCC diagnosis are presented in Table 1. 
Patients who developed HCC were older (p<0.001), had higher prevalence of type 2 diabetes (T2DM; 
p<0.001), and of severe fibrosis (stage F3-F4) than those who did not (Table 1), whereas sex 
distribution and prevalence of obesity were not different (p=NS). Concerning genetic risk factors, at 
univariate analysis HCC development was associated with PNPLA3 and MBOAT7 variants (p<0.001 and 
p=0.003, respectively; Table 1). 
The clinical features of Italian NAFLD-HCC patients according to presence of severe fibrosis are 
reported in Table S1. Patients who developed HCC in the absence of severe fibrosis (n=21, 17%) were 
more frequently males (p=0.040), and carriers of the MBOAT7 rs641738 risk T allele (p=0.006). 
 
MBOAT7 variation is associated with NAFLD-HCC in Italian patients 
The frequency distribution of the MBOAT7 rs641738 C>T polymorphism in Italian NAFLD patients 
stratified by the presence of HCC is shown in Figure 1A. There was a significant over-representation of 
the rs641738 T allele in HCC vs. non-HCC NAFLD patients (p=0.003, Fig. 1a and Table 1). In the NAFLD 
population, which was selected due to referral for suspected steatohepatitis/HCC, there was a 
borderline deviation from Hardy-Weinberg equilibrium for the frequency distribution of the rs641738 
MBOAT7 variant (p=0.03 in both groups). However, the frequency distribution of the rs641738 variant 
did not violate Hardy-Weinberg equilibrium in 243 unselected healthy control subjects (p=NS; Table 
S3). 
The clinical features of Italian NAFLD patients stratified by the rs641738 genotype are shown in Table 
S2. The rs641738 T allele was borderline associated with T2DM (p=0.05) in the overall cohort, but this 
was not confirmed in patients stratified by HCC diagnosis, and was possibly explained by the 
confounding effect of the association between both rs641738 T allele and T2DM with HCC. In HCC 
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patients, the T allele was associated with obesity (p=0.035), and lack of severe fibrosis F3-F4 
(p=0.006). 
As expected, the rs641738 T allele was nearly associated with severe fibrosis (stage F3-F4; OR 1.24, 
95% c.i. 1.00-1.54; p=0.052). The frequency distribution of PNPLA3, TM6SF2, and MBOAT7 variants 
according to hepatocellular carcinoma (HCC) diagnosis in Italian NAFLD patients stratified by the 
severity of fibrosis (stage F0-F2 vs. F3-F4) is presented in Table 2. While the PNPLA3 variant was 
associated with HCC development in patients with (p=0.011), but not in those without severe fibrosis 
(p=NS), the MBOAT7 T allele was associated with HCC in patients without (p<0.001; Fig. 1b and Table 
S), but not in those with (p=0.55; Fig. 1c and Table S) severe fibrosis. 
 
Independent predictors of NAFLD-HCC 
The independent predictors of NAFLD-HCC are presented in Table 3. At univariate analysis (left panel), 
development of HCC was associated with older age, T2DM, and severe fibrosis (p<0.001 for all), 
whereas among the genetic factors with PNPLA3 I148M (p<0.001) and strongly associated with 
MBOAT7 T rs641738 T alleles (OR 2.18, 95% c.i. 1.30-3.63; p=0.003).  
At multivariate logistic regression analysis including as independent variables noninvasive predictors 
of HCC (Model 1, middle panel), which can be applied even in NAFLD patients without histological 
evaluation of liver damage, HCC development was associated with older age (p<0.001), male sex 
(p=0.045), T2DM (p<0.001), PNPLA3 I148M alleles (p=0.010), TM6SF2 E167K alleles (p=0.027), and 
remained strongly associated with MBOAT7 rs641738 alleles (OR 1.81, 95% c.i. 1.24-2.69; p=0.002).  
After further adjustment for the presence of severe fibrosis stage F3-F4 (Model 2), the TM6SF2 E167K 
(p=0.008) and MBOAT7 rs641738 T (OR per allele 1.65, 95% c.i. 1.08-2.55; p=0.021; OR for T/T vs. C/C 
2.73, 95% c.i. 1.17-6.51, p=0.008) alleles remained significantly associated with HCC risk, whereas the 
effect of the PNPLA3 I148M variant was lost.  
In Model 1, the effect of MBOAT7 variant was larger in patients without severe fibrosis (OR per allele 
2.78, 95% c.i. 1.04-8.71; p=0.050), whereas it was not significant considering only patients with severe 
fibrosis (OR per allele 1.19, 95% c.i. 0.78-2.03; p=0.3). 
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Combined effect of genetic risk factors for NAFLD-HCC 
The relationship between the total number of risk alleles including PNPLA3 I148M, TM6SF2 E167K, 
and MBOAT7 rs641738 T and HCC risk is presented in Fig. 2. There was a significant association 
between the number of risk alleles and HCC (OR per allele 1.56, 95% c.i. 1.31-1.86; OR 9.25, 95% c.i. 
3.83-22.8 between the extremes of the distribution, i.e. 5 vs. 0 risk alleles; p<0.001 for both). HCC risk 
was 9% in the 36% of the population with 0-1 risk alleles, 19% in the 55% of the population with 2-3 
risk alleles, and 31% in the 9% of the population with 4-5 risk alleles. The association held constant 
after correction for other risk factors as in Model 2 (OR per allele 1.68, 95% c.i. 1.30-2.20; OR 13.4, 
95% c.i. 3.71-51.5 between the extremes of the distribution; p<0.001 for both). 
A combined risk score considering acquired and genetic risk factors was developed to predict HCC: 1 / 
(1 + e ^ - ((-12.588 + (0.162 * age) + (0.404 * Sex: 1 if male, -1 if female) + (0.259 * Obesity: 1 present, -
1 absent) + (0.587 * T2DM: 1 present, -1 absent) + (1.299 * Severe Fibrosis: 1 yes, -1 no) + (0.442 * 
number of risk alleles))). The model had a 0.960.4 area under the receiving operating characteristic 
curve (AUROC) for detecting HCC cases. The optimal cutoff (identifying the best combination of 
sensitivity and specificity) had 96% sensitivity and 89% specificity for HCC (Fig. S1). The 
corresponding AUROC of a model taking into consideration only clinical factors was slightly lower 
(0.930.5). In the subgroup of patients without severe fibrosis, the AUROC for clinical factors alone 
was 0.910.5, whereas the full model incorporating genetic risk factors maintained an AUROC of 
0.960.4 (p=NS vs. clinical factors alone).  
 
Relationship between MBOAT7 locus variants and gene expression 
To investigate the biological basis for the stronger association of MBOAT7 locus variation with HCC in 
patients without severe fibrosis, we next examined the association of the rs641738 variant with 
possibly variants that may influence MBOAT7 mRNA stability, and with hepatic MBOAT7 mRNA 
expression levels in patients stratified by the severity of liver fibrosis. 
In 98 severely obese patients, the rs641738 variant was in high linkage with the MBOAT7 3’-UTR 
variant rs8736 C>T polymorphism (R2=0.98; only 1/98 discordant case).  Despite this, the rs8736 
polymorphism was non-significantly more closely associated with NAFLD (p=0.048 vs. p=0.057) and 
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MBOAT7 expression (p=0.042 vs. p=0.046) than rs641738. These data are in line with the hypothesis 
that rs641738 is not the causal variant, but may be in linkage with variants influencing MBOAT7 
expression. 
Gene expression of MBOAT7 in 47 patients from the Hepatology service characterized by more severe 
liver damage (Table S4) is shown in Fig. 3. The rs641738 T allele was associated with reduced hepatic 
MBOAT7 expression in patients absent or mild fibrosis (stage F0-F1; p=0.02), but not in those with 
moderate-severe fibrosis (stage F2-F4; p=0.1). 
 
MBOAT7 variation and NAFLD-HCC risk in UK non-cirrhotic NAFLD patients  
To increase the study power, we next evaluated the association of the rs641738 T allele with HCC risk 
in non-cirrhotic NAFLD patients from UK, whose clinical features are presented in Table S5. The 
frequency distribution of the rs641738 C>T genotype in patients stratified by HCC diagnosis is shown 
in Table 4.  Although in the UK non-cirrhotic NAFLD cohort (N=358, of whom 20 with HCC) MBOAT7 
variation was not significantly associated with HCC (p=0.32), in the overall combined UK/Italian 
cohort of NAFLD patients without advanced fibrosis/cirrhosis the T allele remained associated with an 
increased risk of HCC (allelic OR 2.10, 95% c.i. 1.33-3.31).  
 
Impact of MBOAT7 variation on HCC risk in non-cirrhotic patients with other liver diseases  
We finally evaluated the impact of the rs641738 T allele on HCC risk in 1121 non-cirrhotic patients 
with CHC and ALD (25, 2% with HCC, Table S6). Results are presented in Table 5. The rs641738 T 
allele was associated with increased risk of HCC, independently of age, sex, and the etiology of liver 
disease (OR 1.93 for each T allele, 95% c.i. 1.07-3.58; p=0.035), with an effect size comparable to that 
observed in NAFLD. We observed a similar trend for association of the T allele with non-cirrhotic HCC 
in patients with CHC and ALD analyzed separately (Table S7). The PNPLA3 I148M variant was also 
associated with HCC development outside cirrhosis, with a similar effect size of that of MBOAT7 
variation (Table 5; p=0.021).  
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DISCUSSION 
In this study, we evaluated whether the rs641738 C>T MBOAT7 locus sequence variant, associated 
with the development and progression of NAFLD 31, 32, influences susceptibility to NAFLD-HCC. The 
main result is that in the Italian NAFLD cohort each MBOAT7 rs641738 T allele conferred an 
approximately 80% increased risk of HCC. The association was mostly driven by a strong enrichment 
in the risk T allele in patients without advanced liver fibrosis, suggesting that MBOAT7 variation 
predisposes to HCC development particularly in non-cirrhotic patients. To confirm this hypothesis, we 
also examined the frequency of the MBOAT7 T allele in an independent UK cohort of non-cirrhotic 
NAFLD patients. Although the T allele was not significantly associated with NAFLD-HCC in this 
replication cohort, it remained significant in the combined cohort of 913 non-cirrhotic European 
NAFLD patients (41 with HCC) where it was associated with a greater than 2-fold increased risk of 
NAFLD-HCC; a relatively large effect size for a common genetic variant.  This genetic polymorphism 
might thus represent a first useful biomarker to stratify HCC risk among individuals affected by NAFLD 
without advanced liver fibrosis.  
The MBOAT7 protein catalyzes the transfer of polyunsaturated fatty acids such as arachidonoyl-CoA to 
lyso-phosphatidylinositol, thereby allowing to achieve an adequate level of desaturation in cell 
membranes 31. The rs641738 T allele is associated with reduced MBOAT7 expression and altered 
phosphatidyl-inositol plasma and hepatic composition 31, 32, favoring hepatocellular fat accumulation 
and the production of inflammatory mediators 31. However, rs641738 is not likely the causal variant 
underpinning susceptibility to NAFLD and HCC, as we observed that it is in strong linkage with other 
polymorphisms in 3’-UTR of MBOAT7, which may be more closely related to the phenotype and are 
potentially involved in the regulation of MBOAT7 mRNA stability. 
It could be speculated that the effect size of rs641738 on HCC risk was larger in patients without 
severe fibrosis because the presence of the risk variant may somewhat compensate for the lack of the 
cirrhotic pro-carcinogenic environment. However, we observed that the rs641738 T allele is 
associated with reduced hepatic expression of MBOAT7 31 only in NAFLD patients without severe 
fibrosis. Therefore, the MBOAT7 variant may exert its deleterious effect specifically at early stages of 
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liver disease. Alteration of hepatic parenchymal structure and relative cell-types representation may 
then hamper the impact of the MBOAT7 variant during severe fibrosis, because MBOAT7 is highly 
expressed in hepatic stellate cells and inflammatory cells 31, 33. In keeping with this interpretation, the 
rs641738 T allele was also associated with development of early stages, but not severe fibrosis in 
patients at risk of NASH 31, and in a large cohort of CHC patients 30. Therefore, it the MBOAT7 variation 
might have a dual impact on liver disease during initial stages: either predisposes to HCC development 
before severe fibrosis ensues, or it facilitates the evolution to early-intermediate fibrosis. In line with 
this hypothesis, we also showed that the rs641738 T allele was associated with HCC development in 
non-cirrhotic patients with ALD or CHC. 
In the Italian NAFLD cohort, the overall impact of the MBOAT7 rs641738 on HCC risk was similar to 
that of the I148M PNPLA3 variant. However, the effect of the I148M variant on HCC risk was not 
independent of severe fibrosis, suggesting that the mechanism is partly mediated by promotion of 
hepatic fibrogenesis and alteration of hepatic stellate cells biology 15, 19, 34. Notably, the size effect of the 
PNPLA3 I148M variant was larger and only partially attenuated by the impact on liver fibrosis in a 
previous study conducted in a UK cohort 21. This difference may be due to lifestyle factors, and to the 
higher prevalence of clinical cofactors, as opposed to genetic risk variants (lower frequency of the 
I148M variant) in the UK cohort. In addition, we also report for the first time an association between 
the TM6SF2 E167K variant and NAFLD-HCC. However, this association was not detected by univariate 
analysis due to an interaction of the TM6SF2 variant with clinical factors, and it has previously been 
absent when sought in the UK NAFLD cohort 26, whereas a predisposing effect on HCC was reported in 
a Italian cohort of patients with alcoholic cirrhosis 28. Further studies are therefore required to confirm 
whether the E167K variant is an independent risk factor for HCC. 
All in all, data suggest that genetic variants predisposing to hepatic fat accumulation promote hepatic 
carcinogenesis. Indeed, hepatocellular fat accumulation represents a key feature of hepatic 
carcinogenesis 35, 36. Therefore, they might represent useful biomarkers for risk stratification. In fact, in 
the Italian NAFLD cohort the number of genetic risk variants carried was strongly associated with 
HCC, with 13.4-fold higher risk in those carrying five risk variants as compared to none. Remarkably, 
the number of genetic risk variants was able to classify NAFLD patients in three groups with different 
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HCC risk: 9% in the 36% of patients with 0-1 risk alleles, l9% in the 55% with 2-3 risk alleles, and 31% 
in those carrying more than 3 risk alleles. This could in principle allow a better stratification of HCC 
risk than those allowed by the PNPLA3 I148M variant alone, which was proposed by the EASL-EASD-
EASO NAFLD guidelines 21, 37. However, in the present cross-sectional Italian cohort genetic risk 
variants did not significantly improve the predictive accuracy of clinical factors. 
Limitations of the study include its cross-sectional retrospective nature, resulting similarly to previous 
reports 21 in an uneven representation of clinical risk factors (age, sex, T2DM, severe fibrosis) between 
HCC cases and controls. However, the majority of NAFLD-HCC patients are still diagnosed incidentally 
outside regular follow-up 38, so that prospective studies in patients with advanced disease would not 
be more informative, especially for the risk of non-cirrhotic NAFLD-HCC. This could have led to an 
underestimation of the impact of inherited genetic risk variants on NAFLD-HCC, whereas the impact of 
clinical risk factors may have been overestimated. Therefore, the weight of specific factors in 
determining the HCC risk score should be reassessed in larger prospective cohorts with long follow-up 
and availability of the genetic risk profile before evaluation of genetic risk variants can be considered 
for implementation in clinical practice. Due to the relatively low number of patients included, these 
limitations are particularly relevant for the association of MBOAT7 variation with HCC development in 
patients without severe liver fibrosis. Finally, these results may not be applicable to other ethnic 
groups. 
In conclusion, the MBOAT7 rs641738 T allele is associated with reduced MBOAT7 expression and may 
predispose to HCC in European individuals without cirrhosis, suggesting it should be evaluated in 
future prospective studies aimed at stratifying NAFLD-HCC risk. 
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METHODS 
 
Patients 
We enrolled 132 consecutive unrelated patients with NAFLD-HCC of Italian descent, referred between 
January 2008 and January 2015 to the Milan, Udine, Turin, Rome, and Palermo hospitals, for whom 
DNA samples were available. Diagnosis of HCC was based on the EASL–EORTC Clinical Practice 
Guidelines 7. In the absence of liver biopsy, diagnosis of NAFLD required detection of ultrasonographic 
steatosis plus at least one criterion of the metabolic syndrome.  
As controls, we selected Italian-ancestry patients with histologically confirmed NAFLD followed at the 
same referral outpatient Hepatology services during the same study period 27, 39, from a recently 
published database 31, who did not develop HCC during follow-up. We did not consider for this study 
bariatric patients from Milan because of the different recruitment criteria (indication to metabolic 
surgery), leading to different demographic and clinical features 27, 39, and the lack of incident HCC cases 
in the cohort.  
All patients were tested for secondary causes of steatosis including alcohol abuse (≥ 30/20 g/day in 
M/F) and the use of drugs known to precipitate steatosis. Viral and autoimmune hepatitis, hereditary 
hemochromatosis, Wilson’s disease, alpha-1-antitrypsin deficiency and present or previous active 
infection with HBV and HCV were ruled out using standard clinical and laboratory evaluation, as well 
as liver biopsy features.  
Advanced fibrosis was defined in the presence of fibrosis stage F3-F4 40, when liver biopsy was 
available. In HCC patients with radiological diagnosis, advanced fibrosis was defined in the presence of 
clinical, endoscopic or ultrasonographic signs of portal hypertension or cirrhosis (n=46), or of liver 
stiffness ≥ 8.4 kPa evaluated by elastometry (n=3), or by a positive NAFLD fibrosis score (n=5) 41. 
Obesity was defined when BMI>30 Kg/m2. All NAFLD patients without HCC included in the study 
underwent liver biopsy, while among those who developed HCC, fibrosis staging was histologically 
performed in 78 (59%) of the cases. Clinical features of subjects included according to the presence of 
HCC are shown in Table 1.  
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The UK NAFLD cohort comprising HCC cases and controls recruited at a single tertiary centre (the 
Freeman Hospital, Newcastle-upon-Tyne, UK) has previously been described 21. The study had all the 
necessary ethical approvals and all participants gave informed consent. For this study, we considered 
patients for whom liver disease staging scored according to the NASH CRN histopathological system 
and DNA samples for MBOAT7 genotyping were available. Clinical features of the 358 individuals 
analyzed in this study are presented in Table S5. 
 
We next evaluated the impact of the rs641738 variant on HCC risk in an Italian multicenter cohort of 
non-cirrhotic patients with chronic hepatitis C (CHC; n=597) and alcoholic liver disease (ALD; n=524). 
CHC patients were from the well-described histological Milan CHC cohort 42, 43, whereas HCC cases 
were previously described by our group (Milan HCC cohort, where presence of cirrhosis was carefully 
assessed) 44. 
ALD patients with and without HCC included patients from the Milan center, which were partly 
described previously (again the Milan HCC cohort), and for whom liver disease was evaluated by 
histology or as described above for NAFLD 44. We also considered consecutive individuals, who were 
admitted to the Outpatient Clinic at the Department of Clinical Medicine, Policlinico Umberto I, Rome 
for alcohol abuse or dependence between 2005 and 2014, for whom DNA samples were still available 
and genotyping was successful 45. At-risk alcohol consumption was defined as ≥3/2 alcohol units per 
day for M/F, respectively. Cirrhosis was ruled out based on the presence of at least one of the following 
features: (i) current or past cirrhosis complications; (ii) the presence of at least two parameters among 
hyperbilirubinaemia, hypoalbuminaemia, prolonged prothrombin time, low platelet count, irregular 
liver surface at ultrasound/CT, reduced portal vein flow at ultrasound, gastroesophageal varices at 
endoscopy, or by histological analysis. Individuals with other coexistent liver diseases were excluded. 
Clinical features of this cohort are presented in Table S6.  
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The study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki, was 
approved by the Ethical Committee of the Fondazione IRCCS Ca’ Granda of Milan, as well as by the 
other involved Institutions, and was performed according to the recommendations of the hospitals 
involved. Informed consent was obtained from each patient. 
 
Genotyping 
Patients were genotyped for rs738409 (PNPLA3 I148M) rs58542926 (TM6SF2 E167K), as previously 
described 27. The rs641738 (located within TMC4 coding sequence, chr19:54676763 positive strand, 
p.G17E protein variant) and rs8736 (located within the 3’-untranslated region – UTR – of MBOAT7) 
MBOAT7/TMC4 locus genotyping has been performed in duplicate by TaqMan 5’-nuclease assays at the 
Metabolic Liver Disease lab, at the University of Milan (Life Technologies, Carlsbad, CA). Genotyping 
success rate was >98%. The duplicate genotype concordance rate was 100%. Genotyping was 
confirmed by direct sequencing of random samples, and concordance rate was 100% (primers are 
available upon demand). 
 
Gene expression analysis 
Expression of MBOAT7 and TMC4 was determined in two different subsets of patients. The first one 
was made of 98 severely obese patients, with a very low prevalence of advanced liver fibrosis, and has 
previously been described in details 31. This was used to analyze the association of a 3’-untranslated 
region MBOAT7 locus variant, rs8736 possibly influencing MBOAT7 mRNA stability, with MBOAT7 
expression.  The second one was made up of 47 patients from the Hepatology service, and was 
characterized by a higher prevalence of liver fibrosis. Clinical features of these patients are presented 
in Table S4. This was used to evaluate the impact of liver fibrosis on the association between the 
rs641738 variant and MBOAT7 expression. 
MBOAT7 expression was quantified as previously described 31. Association analysis between rs641738 
variant (additive model) and gene expression, and linkage with rs8736 were conducted by the PLINK 
v1.07 genetic analysis software.  
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Statistical analysis  
For descriptive statistics, continuous variables are shown as mean and standard deviation or median. 
Categorical variables are presented as number and proportion. The OR of HCC or severe fibrosis per 
MBOAT7 rs641738 T alleles and other risk factors were estimated by logistic regression models, 
assuming an additive effect of genetic variants, and adjusted for clinical risk factors (the major known 
clinical risk factors for NAFLD-HCC in previous studies) as specified, PNPLA3 I148M and TM6SF2 
E167K genotypes (clinical and genetic factors previously associated with or candidate for liver disease 
evolution to HCC) 21, 26. A NAFLD-HCC risk score was developed according to a previously described 
procedure 41. 
Statistical analyses were carried out using the JMP 13.0 Statistical analysis software (SAS Institute, 
Cary, NC), R statistical analysis software version 3.3.2 (http://www.R-project.org/), and PLINK v1.07 
46. P-values < 0.05 were considered statistically significant. The study methods and results have been 
reported according to the STROBE/STREGA guidelines for genetic association studies. 
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TABLES 
 
Table 1. Clinical features of 765 Italian NAFLD patients stratified by HCC diagnosis. 
 Hepatocellular carcinoma p 
 Yes (n=132) No (n=633)  
Age, years 67.0±8.8 47.5±12.3 <0.001 
Sex, Female 25 (19) 163 (26) 0.25 
Obesity, yes 39 (32) 202 (32) 0.99 
T2DM, yes 84 (64) 124 (20) <0.001 
Severe fibrosis, F3-4 111 (84) 99 (16) <0.001 
PNPLA3, I148M   <0.001 
I/I 31 (23) 231 (36)  
I/M 55 (42) 283 (45)  
M/M 46 (35) 120 (19)  
TM6SF2, E167K   0.30 
E/E 109 (83) 538 (85)  
E/K 19 (14) 88 (14)  
K/K 4 (3) 7 (1)  
MBOAT7, rs641738 C>T   0.003 
C/C 26 (20) 213 (34)  
C/T 69 (52) 285 (45)  
T/T 37 (28) 135 (21)  
 
( ): % values; T2DM: type 2 diabetes mellitus. Comparisons were performed by logistic regression 
setting HCC as dependent variable, and the association of genetic variants was analyzed assuming 
additive models. 
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Table 2. Frequency distribution of PNPLA3, TM6SF2, and MBOAT7 variants according to hepatocellular 
carcinoma (HCC) in 765 Italian NAFLD patients stratified by the severity of fibrosis (stage F0-F2 vs. 
F3-F4). 
 
 
 Fibrosis stage 
 F0-F2  F3-F4  
HCC Yes No p Yes No p 
 Yes (n=21) No (n=534)  Yes (n=111) No (n=99)  
PNPLA3, I148M    0.92   0.011 
  I/I 10 (48) 200 (37)  21 (19) 31 (31)  
  I/M 6 (28) 236 (44)  49 (44) 47 (48)  
  M/M 5 (24) 98 (19)  41 (37) 22 (22)  
TM6SF2, E167K   0.11   0.50 
  E/E 16 (76) 458 (86)  93 (84) 80 (80)  
  E/K 4 (19) 70 (13)  15 (13) 18 (19)  
  K/K 1 (5) 6 (1)  3 (3) 1 (1)  
MBOAT7, rs641738    <0.001   0.55 
  C/C 1 (4) 183 (35)  25 (22) 30 (30)  
  C/T 10 (48) 243 (45)  59 (53) 42 (43)  
  T/T 10 (48) 108 (20)  27 (25) 27 (27)  
 
( ): % values. HCC. Hepatocellular carcinoma. Comparisons were performed by logistic regression 
setting HCC as dependent variable, and the association of genetic variants was analyzed assuming 
additive models. 
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Table 3. Independent predictors of HCC in 765 Italian patients with NAFLD. 
 Unadjusted Model 1 Model 2 
 OR  95%c .i. p OR 95%c .i. p OR 95%c .i. p 
Age, years 1.20 1.16-1.24 <0.001 1.19 1.15-1.23 <0.001 1.16 1.11-1.21 <0.001 
Sex, Female 0.57 0.41-1.06 0.09 0.52 0.27-0.99 0.045 0.45 0.21-0.91 0.026 
Obesity, yes 1.11 0.75-1.69 0.61 1.69 1.05-2.56 0.069 2.50 1.32-4.76 0.008 
T2DM, yes 7.18 4.81-10.84  <0.001 4.73 2.75-8.30 <0.001 3.33 1.75-6.44 <0.001 
Severe fibrosis, F3-F4 28.9 17.6-49.5 <0.001 NA NA NA 12.5 6.36-6.1 <0.001 
PNPLA3, n I148M alleles 1.70 1.32-2.21 <0.001 1.61 1.12-2.32 0.010 1.31 0.86-2.03 0.24 
TM6SF2, n E167K alleles 1.27 0.82-1.92 0.27 1.99 1.08-3.65 0.027 2.80 1.33-6.10 0.008 
MBOAT7, n T alleles 2.18 1.30-3.63 0.003 1.81 1.24-2.69 0.002 1.65 1.08-2.55 0.021 
 
OR: odds ratio of HCC, 95% c.i.: 95% confidence interval; T2DM: type 2 diabetes mellitus; n: number of 
at risk alleles. Comparisons were performed by logistic regression setting HCC as dependent variable, 
and the association of genetic variants was analyzed assuming additive models. Model 1: adjusted for 
age, sex, obesity, and T2DM; Model 2: further adjusted for presence of advanced fibrosis; NA: not 
addressed. 
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Table 4. Frequency distribution of the rs641738 C>T genotype in 913 patients without advanced liver 
fibrosis/cirrhosis from the Italian and UK cohorts stratified by HCC diagnosis. 
 Hepatocellular carcinoma   
 YES NO p* OR (95% c.i.) 
Italy, n= 21 534   
MBOAT7, rs641738 C>T   <0.001 3.09 (1.58-6.02) 
C/C 1 (4) 183 (35)   
C/T 10 (48) 243 (45)   
T/T 10 (48) 108 (20)   
UK, n= 20 338   
MBOAT7, rs641738 C>T   0.32 1.39 (0.71-2.71) 
C/C 4 (20) 97 (29)   
C/T 11 (55) 179 (53)   
T/T 5 (25) 62 (18)   
OVERALL, n= 41 872   
MBOAT7, rs641738 C>T   0.001 2.10 (1.33-3.31) 
C/C 5 (12) 280 (32)   
C/T 21 (51) 422 (49)   
T/T 25 (37) 170 (19)   
 
* Comparisons were performed by logistic regression setting HCC as dependent variable, and the 
association of genetic variants was analyzed assuming additive models. (): % values; OR, 95% c.i.: 
allelic odds ratio and 95% confidence intervals. 
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Table 5. Independent predictors of hepatocellular carcinoma (HCC) in 1121 non-cirrhotic patients 
with chronic liver diseases associated with hepatic fat accumulation (597 with chronic hepatitis C and 
524 with alcoholic liver disease). 
 
 HCC    
 No (n=1096) Yes (n=25) p value Allelic OR, 95% c.i.* p 
value* 
PNPLA3 I148M  558/437/101 
(51/40/9) 
8/10/7 
(32/40/28) 
0.016 1.92, 1.07-3.45  0.021 
TM6SF2 E167K 973/122/1 
(89/11/0) 
20/5 
(80/20) 
0.16 1.96, 0.61-5.27 0.16 
MBOAT7/TMC4 rs641738 C>T 327/510/259 
(30/46/24) 
2/15/8 
(8/60/32) 
0.028 1.93, 1.07-3.58 0.035 
 
(): % values; OR: odds ratio; c.i.: confidence interval. Comparisons were performed by logistic 
regression setting HCC as dependent variable, and the association of genetic variants was analyzed 
assuming additive models. * Adjusted for age, sex, liver disease etiology, and PNPLA3, TM6SF2 and 
MBOAT7/TMC4 genetic variants. 
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FIGURE LEGENDS 
 
Figure 1. Frequency distribution of the MBOAT7 locus rs641738 T allele in 765 Italian NAFLD patients 
stratified by the presence of hepatocellular carcinoma (HCC). A) Overall cohort; B) patients with stage 
F0-F2 fibrosis; C) patients with stage F3-F4 fibrosis. Comparisons were performed by logistic 
regression setting HCC as dependent variable, and the association with the MBOAT7 variant was 
analyzed assuming an additive model. 
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Figure 2. Risk of hepatocellular carcinoma according to the number of PNPLA3 I148M, TM6SF2 E167K, 
and MBOAT7 rs641738 C>T risk variants in 765 Italian patients with NAFLD. HCC: hepatocellular 
carcinoma; SE: standard error. Comparisons were performed by a multivariate logistic regression 
setting HCC as dependent variable, and the association with genetic risk factors (numbers of at risk 
alleles carried) was analyzed assuming an additive model. p<0.001 for the association of the number 
of risk alleles with HCC, both at unadjusted analysis and after adjustment for age, sex, obesity, T2DM, 
and presence of advanced fibrosis stage F2-F4. 
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Figure 3. Impact of the presence of rs643718 risk T allele on MBOAT7 expression (log mRNA levels) in 
47 patients with NAFLD from the Milan Hepatology service stratified by the presence of clinically 
significant hepatic fibrosis (stage F2-F4). Data were compared by Student’s t-test. 
 
 
 
